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ABSTRACT  
Objective: To investigate the effect of valencene on dearrangement in glycoprotein levels in the streptozotocin(STZ)-nicotinamide(NA)induced 
diabetic rats. Materials and Methods: Diabetes was induced in experimental rats by a single intraperitoneal (i.p) injection of STZ (45 mg/kg 
b.w) dissolved in 0.1 M citrate buffer (pH 4.5) 15 minutes after the i.p injection of NA (110 mg/kg b.w). The levels of glycoproteins were altered 
in experimental diabetes mellitus. Valencene were administered to diabetic rats intragastrically at 100 & 200mg/kg bw for 30days. The effects 
of valencene on plasma glucose, insulin, plasma and tissue glycoproteins were studied. Results: Oral administration of valencene (200mg/kg 
b.w)for 30d, dose dependently improved the glycemic status in STZ-NA induced diabetic rats. The levels of plasma glucose were decreased with 
significant increase of plasma insulin level. The altered levels of plasma and tissue glycoprotein components were restored to near normal. 
Conclusions: The results of the present study show the potent beneficial effects of valencene in modifying the levels of glycoprotein 
components in plasma and tissues of diabetic rats. 
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INTRODUCTION 
Diabetes mellitus (DM) is a chronic metabolic disorder that 
causes many serious health problems and impaired quality 
of life for millions of people, worldwide. Globally, the 
prevalence of DM is on the increase. The international 
Diabetes Federation (IDF) estimates that on a global scale, 
the prevalence of diabetes will increase from 425 million 
people in 2017, to 629 million people by 2045[1]. DM is 
characterized by increased blood glucose level as a result of 
disrupted insulin-signalling, which leads to insulin 
deficiency resulting from autoimmune destruction of 
insulin-producing b-cells in the case of type-1DM, or insulin 
resistance and declining β-cell function in type-2 DM. The 
type-2 DM accounts for more than 90–95% of all cases of DM 
globally. It has been reported that prolonged exposure to 
uncontrolled chronic hyperglycemia in DM can lead to the 
impairment of the metabolism of glucose, lipids, proteins 
and glycoprotein components [2]. 
Glycoprotein is a conjugated protein covalently linked to one 
or more carbohydrate groups. They participate in various 
biological events such as cell–cell communication, protein 
stability, function, turnover, membrane transport, cell 
differentiation and recognition[3]. Thay are found on the 
surface of all cells and some are released into the 
bloodstream and body fluids, making blood and plasma 
more viscous. It is well-documented that the carbohydrate 
moieties of glycoprotein components, such as hexose, 
hexosamine, sialic acid and fucose are hydrophilic, make 
glycoproteins far more hydrophilic and allows the protein to 
fold into proper geometry and ensure stability[4]. The 
carbohydrate structure of glycoprotein components is 
altered in many pathological conditions, including DM [5]. 
Impaired metabolism of glycoprotein components may play 
a vital role in the pathogenesis of hepatic and renal diseases 
in DM. However, insulin deficiency during DM produces 
derangement of glycoprotein components metabolism, 
resulting in the thickening of the basal membrane of 
pancreatic cells. Further, an increase in the levels of 
glycoprotein components in diabetics indicates angiopathic 
complications [6]. 
Several modern drugs are effective in preventing DM, but 
their prolonged use may lead to adverse effects. Hence, 
considerable attention has been shifted to the use of dietary 
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constituents and natural products as an alternative or 
complimentary treatment for diabetic medication to reduce 
the adverse effects caused by the synthetic drug. In recent 
years, terpenoids are extensively studied upon various 
diseases including diabetes. It has been documented to 
posses pharmacological effects against various diseases. 
valencene((3R,4aS,5R)-4a,5-Dimethyl-3-(prop-1-en-2-yl) 
1,2,3,4,4a,5,6,7octahydronaphthalene) (Figure.1), is a 
sesquiterpene, is found in the essential oils of citrus fruits, 
grape, and citrus derivatives, etc [7]. It possesses 
pharmacological activities such as antimicrobial [8], anti-
oxidant [9], anticancer [10] and anti-inflammatory 
properties [11]. 
To date, no such information exists to explain the effect  of 
valencene on the components of glycoprotein in diabetic 
rats. Therefore, the present study was designed to assess the 
role of valencene on the levels of plasma and tissue 
glycoprotein components in streptozotocin (STZ)-
nicotinamide (NA)-induced diabetic rats. Recently, we 
reported that valencene at 200 mg/kg b.w. exhibited 
significant antidiabetic effect (Paari et al 2019),Therefore, 
the same dose was fixed in the present study. 
 
Figure.1. Chemical structure of Valencene ((3R,4aS,5R)-
4a,5-Dimethyl-3-(prop-1-en-2-yl) 1,2,3,4,4a,5,6,7-
octahydronaphthalene) 
 
2. MATERIAL AND METHODS 
2.1. Animals  
Adult male albino Wistar rats (180–200 g) were obtained 
from the Central Animal House, Department of Experimental 
Medicine,  Rajah  Muthiah  Medical  College  and  Hospital, 
Annamalai  University  and  maintained at a constant 
temperature (25±1°C) on a 12 h light/12 h dark cycle with 
feeds (National Institute for Nutrition, Hyderabad, India) 
and water was  provided  ad libitum. All animals used in this 
study were cared for according to the Care and Use of 
Laboratory Animals Guidelines by Ministry of Social Justices 
and Empowerment, Government of India. The experimental 
protocol was approved by the animal ethics committee of 
Rajah Muthiah Medical College and Hospital (Reg. No. 
160/1999/CPCSEA, Proposal number:1176, 2017), 
Annamalai University, Annamalainagar. 
2.2. Induction of diabetes 
Diabetes was induced in overnight-fasted experimental 
animals by a single intraperitoneal (i.p) injection of STZ (45 
mg/kg b.w.), dissolved in citrate buffer (0.1M, pH 4.5), 15 
min after the i.p administration of NA (110 mg/kg b.w.) [12] 
Hyperglycemia was confirmed by measuring plasma glucose 
levels 72 hours after STZ injection. Animals with plasma 
glucose levels greater than 250 mg/dL were used in the 
present study. 
A total of 36 rats (24 diabetic rats and 12 normal rats) were 
used and they were divided into six groups with six rats in 
each group as follows: 
Group I: Normal control (vehicle treated) 
Group II:Normal rats received valencene (200 mg/kg b.w) 
intragastrically suspended in 1 mL corn oil for 30 days 
Group III:Diabetic control  
Group IV:Diabetic rats received valencene (100 mg/kg b.w) 
intragastrically suspended in 1 mL corn oil for 30 days 
Group V:Diabetic rats received valencene (200 mg/kg b.w) 
intragastrically suspended in 1 mL corn oil for 30 days 
Group VI:Diabetic rats received glibenclamide (600 µg/kg 
b.w) intragastrically in aqueous solution for 30 days. 
At the end of the experimental period, all the animals were 
fasted overnight, anaesthetized and sacrificed by cervical 
dislocation. Blood samples were collected in tubes 
containing potassium oxalate and sodium fluoride (3:1) 
mixturefor the estimation of fasting plasma glucose. The 
liver and kidney were dissected out, washed in ice-cold 
saline and stored at -80°C until used. The liver and kidney 
were weighed and 10% tissue homogenate was prepared 
with 0.1 M Tris–HCl buffer, pH 7.4. After centrifugation, the 
clear supernatant was obtained and used for biochemical 
assays. 
Biochemical estimations 
Extraction of glycoprotein components 
To 0.1 mL of plasma, 5.0 mL of methanol was added, mixed 
well and centrifuged for 10 min at 3000×g. The supernatant 
was decanted and the precipitate was again washed with 5.0 
mL of 95% ethanol, recentrifuged and the supernatant was 
decanted to obtain the precipitate of glycoprotein 
components. This was used for the estimation of hexose, 
hexosamine, fucose and sialic acid in plasma. For the 
extraction of glycoprotein components from the tissues 
(liver or kidney), a known weight of the tissue was 
homogenized in 7.0 mL of methanol. The contents were 
filtered and homogenized with 14 mL of chloroform. This 
was filtered and the residue was successively homogenized 
in chloroform:methanol (2:1v/v) and each time the extract 
was filtered. The residue (defatted tissues) was obtained and 
the filtrate was decanted. A weighed amount of defatted 
tissue was suspended in 3.0 mL of 2 N HCl and heated at 90C 
for 4 h. The sample was cooled and neutralized with 3.0 mL 
of 2 N NaOH. Samples from this were used for the estimation 
of hexose, hexosamine, sialic acid and fucose in tissues [13]. 
Determination of glycoprotein components levels 
Hexose was estimated by the method of Niebes (1972)[14]. 
The reaction mixture contained 0.5 mL of tissue 
homogenate/plasma, 0.5 mL of 5%phenol and 2.5 mL of 
conc. H2SO4 and boiled for 20 min, and absorbance was 
read at 490 nm. 
Hexosamine was estimated by the method of Elson and 
Morgan (1933) [15] with slight modifications by Niebes 
(1972). Briefly, the reaction mixture contained 0.5 mL 
plasma/1.0 mL tissue homogenate and 2.5 mL of 3 N HCl. It 
was boiled for 6 h and neutralized with 6 N NaOH. To 0.8 mL 
of the neutralized sample,0.6 mL of acetyl acetone reagent 
was added and boiled for 
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30 min. The mixture was treated with 2.0 mL of Ehrlich’s 
reagent. The colour developed was read at 540 nm 
colorimetrically.  
Sialic acid was determined by the method of Warren (1959) 
[16].In brief, 0.5 mL of tissue homogenate/plasma was 
treated with 0.5 mL of de-ionized water and 0.25 mL of 
periodic acid and incubated at 37C for 30 min. 0.2 mL of 
sodium meta-arsenate and 2.0 mL of thiobarbituric acid 
were added to the reaction mixture which was heated for 6 
min. 5.0 mL of acidified butanol was then added and the 
absorbance was read at 540 nm.  
Fucose was estimated by the method of Dische and Shettles 
(1948) [17] 0.5 mL of tissue homogenate/plasma was 
treated with 4.5 mL of H2SO4 and boiled for 3 min. Cysteine 
hydrochloride reagent (0.1 mL) was then added. After 75 
min in the dark, the absorbance was read at 393 and 430 
nm. The glycoprotein levels were expressed as mg/100 g for 
defatted tissue and mg/dL for plasma 
Statistical analysis 
The experimental results were expressed as means ± SD and 
subjected to one-way analysis of variance (ANOVA), using a 
computer software package (SPSS version 11.5; SPSS Inc., 
Chicago,IL) and the comparisons of significant differences 
among the groups were performed using Duncan’s post that 
has multiple range test (DMRT), p < 0.05 was considered as 
significantly different between means. 
RESULTS 
Effect of valencene on plasma glucose and plasma 
insulin levels 
Table.1 reveals the levels of plasma glucose and insulin in 
normal control and experimental rats. The level of fasting 
plasma glucose was significantly (p<0.05) increased and the 
level of plasma insulin was significantly (p<0.05) decreased 
in STZ-NA induced diabetic control rats as compared to 
normal control rats. Treatment with valencene (200 mg/kg 
body weight) daily for a period of 30 days to diabetic rats 
showed a significant (p<0.05) decrease in the level of plasma 
glucose and a significant (p<0.05) increase in the level of 
plasma insulin when compared to STZ-NA induced diabetic 
control rats. Normal control and valencene treated group did 
not show any significant changes in plasma glucose and 
insulin levels. 
 
Table:1. Effect of Valencene on the levels of plasma glucose and insulin in control and experimental rats. 
           Groups Plasma glucose 
(mg/dL) 
Plasma insulin 
(µU/mL) 
Normal control 86.72  6.60a 15.45  1.17a 
Normal + Valencene (200 mg/kg b.w.) 83.99  6.43a 15.58  1.19a 
Diabetic control 285.76  21.75b 8.41  0.64b 
Diabetic + Valencene (200 mg/kg b.w.) 138.24  10.58c 12.43  0.95c 
Diabetic + glinbenclamide    (600µg/kg b.w.) 112.97 8.64 d 14.62 1.12a  
Each value is mean    SD for six rats in each group. In each group, means with different superscript letter (a–e) differ 
significantly at p < 0.05 (DMRT). 
 
Effect of valencene on plasma glycoprotein components 
Figure:2 shows the changes in the levels of plasma hexose, 
hexosamine, sialic acid, and fucose in normal control and 
experimental rats. There was a significant (p<0.05) increase 
in the levels of plasma hexose, hexosamine, sialic acid, and 
fucose in STZ-NA induced diabetic control rats compared to 
normal control rats. Valencene and glibenclamide treatment 
to STZ-NA induced diabetic rats revealed a significant 
(p<0.05) reduction of hexose, hexosamine, sialic acid and 
fucose in the plasma when compared to STZ-NA induced 
diabetic control rats. Normal control and valencene treated 
group did not show any significant changes in plasma 
glycoprotein components. 
 
 
Figure 2: Changes in the levels of plasma glycoprotein components.  
Each column is mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at 
P<0.05 (DMRT).  
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Effect of valencene on tissue glycoprotein components 
The concentrations of hexose, hexosamine and fucose were 
significantly (p<0.05) increased in the liver and kidney 
whereas the concentration of sialic acid was significantly 
(p<0.05) decreased in the liver and kidney of STZ-induced 
diabetic control rats compared to normal control rats. 
Valencene and glibenclamide treatment significantly 
(p<0.05) decreased the concentration of hexose, 
hexosamine, fucose and significantly (p<0.05) increased the 
concentration of sialic acid in the liver and kidney of STZ-NA 
induced diabetic rats when compared to STZ-NA induced 
diabetic control rats (Figures:3 and Figures: 4). Normal 
control and valencene treated group did not show any 
significant changes in tissue glycoprotein components .
 
 
Figure 3: Changes in the levels of liver glycoprotein components. 
Each column is mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at 
P<0.05 (DMRT). 
 
 
Figure 4: Changes in the levels of kidney glycoprotein components. 
Each column is mean ± SD for six rats in each group. Values not sharing a common superscript letter differ significantly at 
P<0.05 (DMRT). 
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DISCUSSION  
Diabetes is a progressive disease whose biochemical basis 
for progression and complications are poorly understood. In 
the diabetic state, glucose is redirected through insulin-
independent pathways resulting in enhanced production of 
carbohydrate moieties of glycoproteins. Therefore, there is 
an elevation in the levels of protein-bound hexose, 
hexosamine, fucose, and sialic acid in plasma of diabetic 
animals. 
Glycoproteins are carbohydrate linked protein 
macromolecules found in the cell surface, which form the 
principle components of animal cells. They play an 
imporatant role in membrane transport, cell differentiation 
and recognition, the adhesion of macromolecules to cell 
surface and the excretion and absorption of macromolecules 
[18]. Prolonged elevation of blood glucose in diabetes may 
result in structural and functional alteration of both 
circulating and membrane bound proteins [19]. Alterations 
in the diabetic state of the composition of the carbohydrate 
components of glycoproteins, especially serum glyloproteins 
and glycoproteins of the capillary basement membrane have 
been reported [20]. 
In diabetic state, abnormalities of glycoprotein metabolism 
are commonly observed [21]. In ours study, we have noted 
the elevated levels of hexose, hexosamine, fucose and sialic 
acid in the plasma and tissues (liver and kidney) of 
streptozotocin induced diabetic rats. The secretion or 
shedding from cell membrane glycoconjugates into the 
circulation leads to the elevation of plasma glycoprotein 
components. Also, insulin deficiency and high levels of 
plasma glucose in diabetic condition may result in an 
increased synthesis of glycoprotein components [22]. 
Valencene and glibenclamide treatment to STZ-induced 
diabetic rats significantly decreased plasma glycoprotein 
components to near normal levels, by virtue of its 
antihyperglycaemic effects. 
Hexosamine a nitrogenous sugar in which an amino group 
replaces a hydroxyl group. The level of hexosamine 
increased significantly in the plasma and tissues of diabetic 
rats, which may be due to insulin deficiency. Further, the 
concomitant oxidative stress increases the expression of 
GFAT (Glutamine: Fructose 6-phosphate amino transferase), 
the rate-limiting enzyme of this pathway leading to higher 
hexosamine levels [23]. Protein-bound hexose in the cell 
membrane provides hydrophobic nature. In this study, we 
observed increased levels of hexose in the plasma and 
tissues of diabetic rats, which may be due to depressed 
utilization of glucose by insulin-dependent pathway,thereby 
enhancing the formation of hexose and hexosamine for the 
accumulation of glycoproteins [24].Treatment with 
valencene and glibenclamide significantly lowered hexose 
and hexosamine levels, which might be due to its 
antihyperglycaemic effects. 
Sialic acid (SA) can be used as a measurement of the acute 
phase response because many of these glycoproteins have 
sialic acid as the terminal, non-reducing positions of 
carbohydrate chains on the outer and inner membrane 
surfaces [25]. SA is an acetylated derivative of neuraminic 
acid and is an essential component of glycoproteins and 
glycolipids. Vascular endothelium carries a high 
concentration of sialic acid where it governs permeability. It 
is necessary for the cell surface residency of platelet and 
promotes endothelial barrier integrity. It also acts as a co-
factor of many cell receptors and is positively associated 
with most of the serum acute phase reactants. In diabetic 
state, extensive micro vascular damage sheds sialic acid into 
circulation. Several studies have highlighted that sialic acid 
metabolism is drastically altered in diabetic condition. Such 
an elevation of sialic acid level in the plasma leads to 
complications like retinopathy, nephropathy and 
neuropathy. A recent study of Prajna et al [26],states that 
increased SA is a potential risk factor for development of 
nephropathy in diabetic patients. Similarly raised levels of 
serum SA is implicated in cardiovascular diseases. 
However,decreased level of sialic acid is observed in the 
tissues of diabetic rats which may be related to increased 
synthesis of fibronectin, which contains sialic acid in its core 
structure. Further, the decreased tissue sialic acid level is 
associated with oxidative stress-induced desialylation of 
glycoproteins [27]. In our study, a significant elevation in 
plasma sialic acid with a fall in hepatic and renal tissues was 
observed in diabetic control rats. Oral administration of 
valencene to diabetic treated rats significantly restored the 
levels of SA in plasma, hepatic and renal tissues to near 
normal which is comparable with glibenclamide. 
Fucose is member of a group of essential sugars that the  
body requires for functioning of cell to cell communication 
and its metabolism appear to be altered in various disease 
conditions such as diabetes mellitus[28]. Arise in fucose 
levels could be due to increased glycosylation in the diabetic 
state. In diabetes, three proteins (haptoglobin, a1acid 
glycoprotein and a1-antitrypsin) synthesized in the liver are 
mainly responsible for the increase in fucose levels. The 
metabolism and synthesis of these proteins may be altered 
in diabetes leading to changes in plasma in the 
hyperglycemic state accelerates the synthesis of 
glycoproteins. Due to increased glycosylation in the diabetic 
state the fucose levels could be increased. Oral 
administration of valencene treatment to STZ-NA induced 
diabetic rats significantly decreased fucose concentration, 
which may be due to the regulation of the fucosylated 
protein levels, by its antihyperglycaemic effects. 
CONCLUSION 
From the above findings, we conclude that valencene 
ameliorated glycoproteins components in STZ-NA induced 
diabetic rats. Valencene through its insulinotropic effect on 
remnant pancreatic β-cells reversed the altered glycoprotein 
levels in plasma, hepatic and renal tissues of diabetic rats 
and thus serves as a promising agent in the management of 
diabetes mellitus. 
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